Conclusion
critically ill, MERS
CRITICALLY ILL, MIDDLE EAST RESPIRATORY SYNDROME
This study demonstrates the presence of type I IFN auto‐Abs in hospitalized patients with MERS.

King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
This research is funded by the King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, Grant No. RC15/142/R/CT.
Approximately 25% of hospitalized patients with Middle East respiratory syndrome (MERS) have type I interferons (IFNs) autoantibodies. These autoantibodies were more prevalent in critically ill patients. 90‐day mortality and other clinical outcomes were similar between patients who were auto‐Abs positive and negative. The effect of treatment with IFN beta‐1b and lopinavir‐ritonavir did not significantly differ between patients who were auto‐Abs positive and those who were auto‐Abs negative.
Mohammed 